[Special Stock] Samchundang Pharm Hits Upper Limit on Success of Bioequivalence Test for Obesity Drug "Rybelsus"

Samchundang Pharm surged to the upper price limit early in trading on July 23. This sharp rise is attributed to strong buying interest following the news that the company had successfully completed a bioequivalence test for a generic version of the oral obesity treatment "Rybelsus."

As of 9:54 a.m. on this day, shares of Samchundang Pharm on the KOSDAQ market were up 29.71%, the maximum daily increase, trading at 213,500 won. The stock opened at 166,100 won and extended its gains, also reaching a new 52-week high.

On this day, Samchundang Pharm announced that its oral GLP-1 generic under development had successfully passed a bioequivalence test compared to the original drug, "Rybelsus" by Novo Nordisk. The Cmax (maximum blood concentration) and AUC (drug exposure) values matched 100% with those of the original. GLP-1 class treatments have recently dominated the diabetes and obesity treatment markets and are experiencing rapid growth.

Samchundang Pharm is recognized for having used a substance (SNAC Free) developed with its S-PASS platform technology, which converts injectable drugs to oral formulations, to avoid multiple original composition patents while successfully reproducing efficacy equivalent to the original.

A company representative stated, "The goal of developing a Rybelsus generic is to enter the market faster than competitors by replicating the original while circumventing patents. Through this test, we have demonstrated not only the high absorption rate of the S-PASS platform but also its precise absorption control technology."